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Abstract 
Purpose: The purpose of the present study was to investigate the possible role of Ki-67 and 
argyrophilic nucleolar organizing regions (AgNOR) between the recurrent and nonrecurrent 
keratocystic odontogenic tumors (KCOTs). Another aim was to compare the correlation 
between these two markers.  
Materials and Methods: 22 KCOTs were evaluated retrospectively. The actual proliferative 
activity of the KCOT was measured by Ki-67 labelling index and argyrophilic nucleolar or-
ganizing regions AgNOR count per nucleus. Results: Recurrence occurred in 3 patients 
(13.6%) during the follow-up period (mean follow-up, 37.8 months) The Ki-67 and AgNOR 
counts were significantly higher in the recurrent lesions comparing to the non-recurrent le-
sions. (p=0,045; p=0,049) The correlation between Ki-67 and AgNOR counts was found to be 
positive (r=0,853 p=0,0001). 
Conclusion: Within the limit of the present study, it is thought that Ki-67 and AgNOR might 
be helpful as a prognostic marker for the recurrences of KCOTs. These markers reinforced 
the meaning of the new classification of the lesion as an odontogenic tumor. Enucleation with 
curettage or decompression following enucleation with curettage is a simple and appropriate 
surgical model for the treatment of KCOT despite the relative high recurrence rate. On the 
other hand, the conservative treatment can be chosen only if there is no coronoid invasion, no 
interruptive cortical lysis and no tissular invasion. 
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Introduction 
Keratocystic odontogenic tumor (KCOT) defined 
by the  World  Health  Organization (WHO), is a be-
nign, intraosseous neoplasm of dental origin, with a 
characteristic  lining  of  parakeratinized  stratified 
squamous  epithelium  (1).  Increased  activity  of  the 
epithelium, has been confirmed by previous studies 
that have compared KCOTs with other odontogenic 
cysts may explain the high recurrence rates of KCOTs. 
Some are associated with nevoid basal cell carcinoma 
syndrome (2). 
Immunohistochemical  studies  have  examined 
KCOTs by using various markers of proliferation and 
of apoptosis. The proliferative activity of the epithelial 
lining of KCOTs has been the subject of various in-
vestigations by using different markers of prolifera-
tion as Ki-67 (2). Ki-67 is the prototypic cell cycle re-
lated nuclear protein, expressed by proliferating cells 
in  all  phases  of  the  active  cell  cycle.  It  rapidly  de-
grades after mitosis with a half-life of detectable an-
tigen being an hour or less (3). Immunohistochemical 
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detection of Ki-67 has been used to evaluate the pro-
liferative potential of healthy cells as well as of pre-
neoplastic and neoplastic lesions (4). 
Nucleolar organizer regions (NORs) are loops of 
DNA  which  transcribes  to  ribosomal  RNA.  The 
NOR-related protein becomes visible in nucleus by a 
silver-staining  technique  under  a  light  microscope, 
and it has been named argyrophilic protein of NOR 
(Ag-NOR)  (5).  Several  different  methods  have  been 
proposed  to  determine  the  proliferative  rate  in  tu-
mors. Silver staining of AgNORs is considered to be 
the best and most cost-effective marker to assess the 
proliferative behaviour of a lesion. The rapidity of the 
cell turnover is evaluated by speed of the cell cycle, so 
as  to  assess  the  growth  rate  of  the  lesion,  which  is 
easily  assessed  by  AgNOR  count  per  nucleus.  The 
amount of AgNOR represents a cell kinetics parame-
ter and can be used for prognostic purposes. AgNOR 
counts have been demonstrated to offer a predictive 
index in various malignancies (6,7). 
Pathologists‟  interest  in  AgNOR  proteins  in-
creased greatly around the end of 1980s following the 
observation that malignant cells frequently exhibit a 
greater AgNOR protein amount as compared with the 
corresponding  benign  or  normal  cells.  AgNOR 
method has become widespread among pathologists, 
in various fields of tumour pathology (8). 
The objective of the present study was to inves-
tigate  clinical  behavior  of  KCOTs  regarding  the  re-
currence, by evaluating Ki-67 and AgNOR staining. 
Another  purpose  was  to  investigate  the  correlation 
between these two markers and to demonstrate their 
possible prognostic role in these lesions. 
 
Material and Methods 
Tissue Samples 
In the present study, KCOTs treated by two oral 
and  maxillofacial  surgeons  from  January  2004  to 
August 2010, were reviewed retrospectively. Clinical 
and  histological  information  was  recorded  for  each 
patient.  The  inclusion  criteria  of  the  study  was  the 
histopathological  diagnosis  of  „„KCOT‟‟.  The  cases 
which  were  previously  treated  in  another  service 
were excluded. The cases followed-up shorter than 1 
year and which were associated with nevoid basal cell 
carcinoma  syndrome  (NBCCS)  were  also  excluded 
from the study. The histopathological diagnosis was 
based  on  the  criteria  showing  parakeratinization  of 
the  lining  epithelium  as  described  by  WHO  guide-
lines (1). 
According  to these  criteria, a total of 22 histo-
pathologically  diagnosed  KCOTs  were  selected  for 
the  study.  Routinely  panoramic  radiographs  were 
used before the operation. CT scans were also used 
according  to  the  clinical  features  (size,  anatomical 
location) of the tumor. The data included; age at di-
agnosis, gender of the patients, location of the lesion, 
clinical  manifestation  (pain,  swelling,  infection) 
treatment modality and recurrence (Table 1). 
All subjects were evaluated clinically and radio-
graphically at regular times. Panoramic radiographs 
were taken at 6 and 12 in the first post-operative year 
followed by once every year. The average follow-up 
period was 37.8 months. 
Immunohistochemical staining 
For  immunohistochemistry,  the  parafin  blocks 
were cut serially into approximately 5 μm thick sec-
tions  on  charged  slides.  Firstly,  the  sections  were 
penetrated  and  dried  overnight  in  an  autoclave  (56 
0C). They were deparaffinized with xylene for 30 min, 
washed  with  99%  alcohol  for  15  minutes,  and  then 
with 96% alcohol and distilled water. Histostain-Plus 
Bulk Kit (Zymed 2nd Generation, LAB-SA Detection 
System, 85-9043) was used in this study. For antigen 
retrieval, the sections were microwaved four times for 
5 min in citrate buffer (Ph 6.0). Endogenous peroxi-
dase activity was blocked by incubating the sections 
with 3% H2O2 and washed with distilled water and 
waited in PBS for 5 min. To prevent non-specific re-
actions, sections were incubated with block solution. 
Ki-67 with a dilution ratio of 1:50 (Zymed Laborato-
ries, Mouse, Monoclonal, Clone 7B11) was used as the 
primary antibody. Slides were incubated with Ki-67 
for 120 min. The secondary antibody was reacted for 
25  min.  AEC  (Zymed  Laboratories,  00-2007,  Lot 
No:319293A)  chromogen  was  used  to  visualize  the 
reaction.  Finally,  the  sections  were  counterstained 
with  Mayer‟s  hematoxylin,  coverslipped  and  evalu-
ated by a light microscope. 
AgNOR staining 
For  AgNOR  staining,  the  paraffin  blocks  were 
cut into approximately 5 μm thick sections. The sec-
tions were deparaffinised with xylene for 30 minutes, 
and  washed  with  99%  alcohol  for  15  minutes,  then 
96% alcohol and distilled water. The slides were im-
mersed in a citric acid solution/ethanol solution (1:3). 
The 50% silver nitrate solution was mixed in 2 g/dL 
gelatin solution dissolved in 1g/dL formic acid in a 
1:2 proportion and the sections were incubated at a 
dark room for 30 min. After washing off the distilled 
water,  the  sections  were  dehydrated  with  ethanol, 
cleared with xylene, and coverslipped and evaluated 





Table 1: Patient demographics and characteristics of the lesions with Kİ-67 and Ag NOR. 
   Gender  Age  Location  Follow-up 
(months) 




1   M  68  Mandible anterior  34   decompression and enucleation with 
curettage 
 -  4  3,60 
2   M  25  Mandible posterior  17   enucleation with curettage   -  3,5  2,70 
3   M  55  Mandible posterior  16   enucleation with curettage   -  3  3,30 
4   M  58  Mandible premolar and anterior  46   enucleation with curettage   -  2,8  2,20 
5   M  65  Mandible premolar and posteri-
or 
65  enucleation with curettage   -  2,3  3,10 
6   F  51  Maxilla premolar and anterior  41  enucleation with curettage   -  4  3,51 
7   F  32  Mandible posterior, ramus  29  decompression and enucleation with 
curettage 
 +  6  4,50 
8   F  32  Mandible posterior  41  enucleation with curettage   -   4  3,60 
9   M  50  Mandible anterior    38   enucleation with curettage   -  5,5  4,60 
10   M  50  Mandible premolar and anterior  38   enucleation with curettage   -   4  3,70 
11   M  37  Maxilla, posterior, premolar, 
anterior 
37   enucleation with curettage    +  4,5  4,00 
12   F  69  Mandible premolar  41   enucleation with curettage   -   4  3,90 
13   M  24  Maxilla premolar, posterior  64   enucleation with curettage   +  4  4,10 
14   M  50  Mandible posterior  19  enucleation with curettage   -  4  3,80 
15   F  40  Mandible posterior  20   enucleation with curettage   -  4,5  4,30 
16   M  62  Mandible premolar  12   enucleation with curettage   -  4,5  4,40 
17   M  56  Mandible premolar  72   enucleation with curettage   -  5  4,45 
18   M  53  Maxilla, posterior, premolar, 
anterior 
53  enucleation with curettage   -   2,5  3,20 
19   M  39  Mandible posterior, premolar,  38  enucleation with curettage   -  3  3,33 
20   F  49  Mandible posterior  39   enucleation with curettage   -  3  4,50 
21   M  58  Mandible posterior  38   enucleation with curettage   -  3  3,70 





Ki-67  immunostained  slides  were  examined  at 
400x magnification in Olympus BX60 microscope. In 
epithelium,  the  positive  and  negative  cells  were 
counted in 5 contiguous and consecutive microscopic 
high-power fields. The number of positive cells was 
divided into the total number of cells counted in the 
whole layer. The result was multiplied by 100 to find 
the percentage of positive cells. AgNOR-stained slides 
were examined at 1000x magnification with immer-
sion oil in Olympus BX60 microscope. The number of 
AgNORs in the nucleus was counted in 250 cells for 
each case. Black dots/aggregated clusters within cel-
lular nucleoli were counted as one dot. The average 
number of AgNORs was divided into total number of 
cells. 
Statistical analysis 
Statistical  analysis  was  aided  by  the  NCSS 
(Number Cruncher Statistical System) 2007 Statistical 
Software  (Utah,  USA).  Chi-square  test  and  Fisher's 
exact test were used to assess qualitative parameters. 
Mann-Whitney-U test was used to evaluate descrip-
tive statistics (median, interquartile range) (SD) and 
differences between groups. Probabilities of less than 
0.05 were accepted as significant. 
Results 
The  ages  of  recurrent  group  members  were 
found to be statistically lower than the non reurrent 
group members (p=0,035). No statistically significant 
difference  was  observed  between  the  recurrent  and 
non  recurrent  groups  regarding  the  follow-up. 




to be statistically higher than the non-recurrent group. 
(p=0,045).  AgNOR  values  of  recurrent  group  were 
found to be statistically higher than the non-recurrent 
group (p=0,049) (Table 2). 
Table 2: Comparison of recurrent and non recurrent 
lesions. 
  Non recurrent  Recurrent  MW  p 
Median (IQR)  Median (IQR) 
Age  51 (40-58)  32 (24-37)  6,5  0,035 
Follow-up  38 (34-50)  42 (37-64)  21  0,472 
Kİ-67  3,5 (3-4)  4,5 (4-6)  8  0,045 
AgNOR  3,6 (3,3-3,9)  4,1 (4-5,5)  8  0,049 
 
Most of the Ki- 67 cells being detected in the su-
prabasal  layers  (Figure  1)  The  AgNOR  dots  were 
higher in the nucleus of subrabasal cells than basal 
cells in KCOT (Figure 2). 
No  statistically  significant  difference  was  ob-
served  between  the  recurrent  and  non  recurrent 
groups regarding the gender (p=0,952). 
No  statistically  significant  difference  was  ob-
served between Kİ-67 and AgNOR regarding the age 
range.  
Statistically  significant  positive  correlation  was 
found  between  Kİ-67  and  AgNOR  values.  (r=0,853 
p=0,0001). (Table 3). 
 
 
Figure  1:  Representative  photomicrograph  of  keratocystic 
odontogenic  tumor  stained  with  Ki-67.  Immunoreactivity  was 




Figure  2: Representative photomicrograph of argyrophilic nu-
cleolar organizing regions (AgNOR) staining. The AgNOR dots 
were higher in the nucleus of subrabasal cells than basal cells in 
keratocystic odontogenic tumour. (x1000) 
 
Table 3: The correlation between AgNOR and Kİ-6. 
     Kİ-67 
AgNOR  r  0,853 




In  our  study,  no  statistically  significant  differ-
ence  was  observed  between  the  recurrent  and  non 
recurrent  groups  regarding  the  gender;  although 
some authors consider that gender could play an im-
portant role in the recurrence rate (9,10). Others con-
sider that the gender is not a significant determinant 
of recurrence (11,12,13). 
The  ages  of  recurrent  group  members  were 
found to be statistically lower than the non-recurrent 
group members (p=0,035). This situation was similar 
to that found by Forssell et al and Gonzalez-Alva et al. 
who reported a higher recurrence rate in young pa-
tients (14, 15). This situation may be associated that 
younger patients often receive more conservative ap-
proach  such  as  preserving  the  associated  teeth  as 
presented in our study. 
Conservative  and  aggressive  approaches  have 
been reported about the management of KCOT. The 
choice  of  the  treatment  must  take  into  account  the 
patient‟s age, size of the lesion, previous recurrence 
history,  soft  tissue  involvement  and  histological 
characteristics (16). In the conservative method, sim-
ple enucleation with or without curettage, marsupi-




sive methods include; peripheral ostectomy, chemical 
curettage with Carnoy‟s solution, and periost, tissue 
or  bone  radical  resection  (17,  18).  The  treatment  of 
KCOTs  is  still  controversial.  A  recent  Cochrane  re-
view demonstrated that there is a need for well con-
ducted randomized controlled clinical trials about the 
management of the KCOTs (19). 
The recurrence rates of reported KCOTs tend to 
vary from 0% to 100% (2, 18, 20, 21). These marked 
discrepancies are thought to be related to the different 
lengths of postoperative follow-up periods, operative 
techniques employed or inclusion of cases with  ne-
void  basal  cell  carcinoma  syndrome  (NBCCS).  Tu-
mors also vary in their aggressiveness, contributing to 
variation in recurrence patterns (18). Recurrence rate 
is  highest  with  the  simple  enucleation  (without  cu-
rettage) and range from 9% and 62.5% (22). Resection 
offers a high cure rate, but produces significant mor-
bidity such as the loss of the jaw continuity or facial 
disfigurement.  It  should  therefore  be  reserved  only 
for aggressive or recurrent lesions, or for patients who 
cannot  be  closely  followed  up  after  conservative 
treatments  (22).  In  our  study,  all  the  cases  were 
treated  with  enucleation  with  curettage  as  reported 
Boffano et al (23). A surgical burr was used to remove 
about 2 mm of cortical bone all around the remained 
bone after enucleation. Only in 2 cases decompression 
was performed before the enucleation with curettage. 
The  recurrence  rate  was  13.6%;  as  similar  with  the 
reports which showed the enucleation and curettage 
as a treatment of KCOT, as presented in our study (18, 
23).  On  the  other  hand  the  recurrence  rate  in  our 
study was found to be as rather low compared with 
previous  reports  which  demonstrated  the  simple 
enucleation method as a treatment of KCOT (24,25,26, 
27). 
The patients are still under periodic observation 
in our institution. On the other it has been reported 
that KCOT may recur even after 6 to 25 years after 
enucleation (25). Therefore it is not possible to draw 
any  long-term  conclusions  on  recurrence  rates  re-
garding the mean follow-up time (37.8 months) of the 
present study. 
It has been reported that KCOTs which were lo-
cated  in  the  mandibular  molar  region  had  signifi-
cantly  higher  recurrence  rates  than  those  in  other 
sites. Difficulty in removing all the traces of the epi-
thelial lining is believed to be a major factor leading to 
recurrence (17). In our study, only one of the recurrent 
lesion was observed in the mandible (no 7 in table 1). 
The lesion size was more than 5 cm and located in the 
posterior part of the mandible, raising up to the con-
dylar process. After 8 months of decompression the 
tumor was enucleated with curettage. 11 months after 
enucleation,  the  lesion  recurred  and  treated  again 
within  the  same  conservative  approach.  The  recur-
rence was associated with the difficult surgical access, 
large size and also biological aggressive behaviour of 
the  lesion  itself  which  was  demonstrated  with  the 
highest Ki67 label index and AgNORs counts. It was 
not possible to remove the tumour in one piece. The 
other two recurrent lesions were seen in the maxilla. 
The lesions sizes were more than 4 cm and the lesions 
were  removed  in  one  piece.  The  sizes  of  the 
non-recurrent tumors vary from 1 to 5 cm. The recur-
rence may be explained with the conservative treat-
ment (root resection) of the associated teeth. Extrac-
tion of teeth has been kept to a minimum. The patients 
denied  multiple  teeth  extractions  and  accepted  the 
risk of recurrence. Therefore it is thought that some 
tumor remnants which were associated with the teeth 
may cause the recurrence as reported Pogrel (28). 
KCOTs  arise  from  odontogenic  epithelial  cells 
and remnants of the dental lamina, and also from ex-
tensions of basal cells of the oral epithelium. Epithelial 
cells in KCOTs seem to have a different proliferative 
potential from those of other odontogenic lesions (4). 
Ki-67  antibodies  are  useful  in  establishing  the 
cell growing fraction in neoplasms. Ki-67 expression 
has  been  shown  to  be  higher  in  the  epithelium  of 
KCOTs when compared with developmental and in-
flammatory cysts, with most of the Ki- 67 cells being 
detected in the suprabasal layers, as reported in our 
study (2, 3, 29). 
Limited numbers of the studies were published 
about the evaluation of AgNORs in odontogenic cysts 
and tumors. Conflicting results have been observed in 
these studies (6, 30,31,32,33,34). Coleman et al. inves-
tigated whether AgNORs may be of value in distin-
guishing various odontogenic cysts from the unicystic 
ameloblastoma. They concluded that AgNOR counts 
are not of diagnostic significance and can not be used 
to distinguish the various odontogenic cysts from one 
another  nor  from  the  unicystic  ameloblastoma  (30). 
Allison  and  Spencer  performed  AgNOR  counts  on 
apical  periodontal  cysts,  dentigerous  cysts,  odonto-
genic keratocysts, ameloblastomas and basal cell car-
cinomas.  They  reported  significant  differences  be-
tween  KCOT  and  apical  periodontal  cyst.  In  that 
study the  mean AgNOR counts for all odontogenic 
cysts ranged between 2.02 and 2.65, and for amelo-
blastomas were 2.24. According the results they con-
cluded that the method had neither a diagnostic nor a 
prognostic value in these lesions (34). In our study, 
the  AgNOR  dots  were  higher  in  the  nucleus  of 
subrabasal cells than basal cells in KCOT. The mean 
values of AgNORs were found higher regarding the 




The differences in the literature may be associ-
ated  with  the  differences  in  staining  method  and 
counting protocol for AgNOR and because of the dif-
ference in simple size. Therefore we are agree with 
Gadbail et al and Eslami et al who recommended a 
standard protocol for AgNOR staining and counting 
protocol (6, 32). 
There  are  several  confounding  factors  for  the 
analysis of relationship between recurrence of KCOT 
and  clinicopathologic  and  immunohistochemical 
variables.  There  is  no  doubt  that  the  surgical  man-
agement is the most influential factor for the recur-
rences following any surgical interventions. However, 
it has not been studied for a group undergoing a sin-
gle surgical procedure for KCOT to reduce the influ-
ence  of  confounding  factors.  Furthermore,  little  is 
known about any relationship between expression of 
cell  proliferative  markers  and  the  recurrence  in  the 
KCOT in terms of recurrent risks for time dependent 
variables (18). The results of our study demonstrated 
higher expression of Ki-67 and AgNOR count in re-
current lesions comparing to non-recurrent lesion. On 
the other hand, Li et al, reported that no significant 
difference between simple (non-recurrent) and recur-
rent lesions regarding the expression of Ki-67 expres-
sion (35). 
The  limitation  of  this  study  is  that  only  two 
markers  have  been  evaluated.  On  the  other  hand, 
important point of this study is the demonstration of 
the  positive  correlation  in  between  Ki-67  and  Ag-
NORs in suprabasal cell layers of KCOTs. This sig-
nificant  positive  correlation  was  also  reported  by 
Gadbail et al (6). 
Another limitation is the low sample size of the 
recurrent  lesions.  In  our  study  the  recurrence  was 
present  only  in  3  out  of  22  subjects.  Similarly,  Ku-
royanagi et al, (18) reported 4 recurred lesions among 
32 subjects diagnosed with KCOT. They reported that 
Ki-67 was found higher in the recurrent group and 
they suggested that this marker can be recommended 
as a prognostic factor. Our results are consisting with 
Kuroyanagi  et  al.  (18)  regarding  the  expression  of 
Ki-67.  Additionally,  according  to  our  results,  we 
recommended  that  AgNOR  might  be  useful  as  a 
prognostic marker in KCOTS.  
Conclusion 
Ki-67 and AgNOR might be useful as a prognos-
tic marker in KCOTs. A standard protocol needed for 
the evaluation of AgNORs. The positive correlation of 
these markers reinforced the neoplastic character of 
the KCOT. The higher expression of these markers in 
recurrent  lesions  is  important  in  order  to  consider 
additional surgical interventions to improve progno-
sis. 
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